Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Biol Macromol. 2014 Jun;67:154-62. doi: 10.1016/j.ijbiomac.2014.02.058. Epub 2014 Mar 13.

Characterization of a Kunitz-type protease inhibitor peptide (Rusvikunin) purified from Daboia russelii russelii venom.

Author information

1
School of Biological Sciences, University of Northern Colorado, Greeley, CO 80639-0017, USA; Department of Molecular Biology and Biotechnology, Tezpur University, Tezpur 784 028, Assam, India. Electronic address: akm@tezu.ernet.in.
2
School of Biological Sciences, University of Northern Colorado, Greeley, CO 80639-0017, USA.
3
Department of Molecular Biology and Biotechnology, Tezpur University, Tezpur 784 028, Assam, India.

Abstract

The snake venom may be considered as a potent source of untapped therapeutic proteins and peptides. The peptide mass fingerprinting and N-terminal sequence alignment of a 6.9kDa peptide named Rusvikunin from Daboia russelii russelii venom show the presence of putative conserved domains of the KU superfamily. Further, BLAST analysis of two of the de novo peptide sequences of Rusvikunin demonstrates significant sequence homology with serine proteases reported in the NCBI database. Rusvikunin possesses conserved cysteine residues and Arg15 at the P1 position. It inhibits amidolytic activity of trypsin (IC50=50nmol/l), plasmin (IC50=1.1μmol/l), and fibrinogen clotting as well as plasma clotting activity of thrombin (IC50=1.3μmol/l); however, it does not inhibit the amidolytic activity of chymotrypsin, thrombin, factor Xa, and tissue plasminogen activator. Rusvikunin is a glycoprotein, demonstrates dose-dependent BAEE-esterase activity. It does not show lethality in mice or in vitro cytotoxicity against mammalian cells but shows in vivo anticoagulant activity 6h after i.p. injection in the mouse model. The commercial polyvalent and monovalent antivenom failed to inhibit the functional properties of Rusvikunin. The possible biomedical applications of Rusvikunin in the treatment and/or prevention of cardiovascular disorders such as thrombosis and trypsin-induced inflammation are suggested.

KEYWORDS:

Anti-plasmin; Anticoagulant; BPTI; Russell's Viper; Thrombin inhibitor; Trypsin inhibitor

PMID:
24632346
DOI:
10.1016/j.ijbiomac.2014.02.058
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center